Search PubMed⌕ Search

Biomedical subjects

S D Delport

Publications and source records attributed to S D Delport.

25 records · Page 2Linked to original sources
PubMed1989

Isolated complete congenital heart block diagnosed prenatally in Down's syndrome; a case report.

A newborn with Down's syndrome complicated by complete atrioventricular (AV) block, despite normal cardiac anatomy, is described. The congenital AV block was diagnosed in utero, and the characteristics of Down's syndrome were recognised after birth. Pitfalls in antenatal diagnosis and management of complete AV block in the fetus are briefly outlined. Identification of fetal karyotype in case of isolated congenital AV block is recommended.

Adult↗
PubMed1988

Breast-feeding practices in a private maternity hospital.

An interview questionnaire study of 51 breast-feeding mothers was conducted to assess the stated policy of breast-feeding promotion in a private maternity hospital. A mean period of 20.6 hours elapsed after delivery before initiation of breast-feeding, and 39.9 hours elapsed before rooming-in took place. At least 47.1% of babies received prelacteal feeds, 94.1% were routinely test-weighed, and 56.9% received complementary feeds. A patient-administered questionnaire is proposed to provide hospital management and attendant medical practitioners with essential feedback that could assist them to close the gap between policy and practice.

Breast Feeding↗
PubMed1988

Serological screening of cord blood for syphilis.

Meticulous antenatal screening for maternal syphilis can prevent congenital syphilis. In the event of inadequate antenatal screening, determination of reagin reactivity on cord blood becomes mandatory. A card test utilising the VDR carbon antigen (Wellcome) was used to screen cord blood samples for reagin reactivity. The same blood was also screened by a reference laboratory, where the VDRL card test was repeated and every result was substantiated by treponemal tests. The VDRL card test done at the local laboratory had a sensitivity of 83,3% and a specificity of 99,8% when compared with the results of the reference laboratory.

Evaluation Studies as Topic↗
PubMed1984

Pharmacokinetics of ceftazidime in premature, newborn and young infants.

The pharmacokinetics of ceftazidime, a new injectable broad-spectrum cephalosporin with high anti-pseudomonal activity, were studied in 50 preterm, full-term and young infants after an intravenous bolus dose of 30 mg/kg. The serum concentrations of ceftazidime were higher in the younger babies, both premature and full-term. In infants over 2 months of age blood levels were similar to those of adult volunteer subjects. No untoward effects were encountered. Considering the in vitro activity of ceftazidime against a wide spectrum of pathogenic bacteria, the present dose schedules, 25-50 mg/kg/d for babies less than 2 months of age and 50-100 mg/kg/d for those 2-12 months of age, appear to be appropriate. Until more experience is gained with ceftazidime in neonates, monitoring of trough levels to ensure adequate blood concentrations would be ideal.

Age Factors↗
PubMed1983

A preliminary pharmacokinetic study of ceftazidime in premature, new born and small infants.

Fifty neonates and infants with suspected or proven bacterial infection were given 30 mg/kg of ceftazidime as a single intravenous dose to investigate the pharmacokinetics of ceftazidime. The mean serum half-lives for babies aged less than 2 months was 4.18 +/- 1.60 h and for those aged 2 to 12 months 2.00 +/- 0.64 h. Dose bands of 25 to 50 mg/kg/day for those less than two months and 50-100 mg/kg/day for those aged 2 to 12 months are recommended for the treatment of suitable bacterial infections.

Bacterial Infections↗